The legal review, led by attorney Juan Monteverde, focuses on whether the merger terms adequately protect the interests of those currently holding common stock in Indivior Pharmaceuticals, Inc. (NASDAQ: INDV). The firm, which maintains offices in the Empire State Building, is inviting shareholders with concerns regarding the deal to review the terms of the acquisition at no personal cost.
In section Releases
Monteverde & Associates Launches Inquiry into Indivior-Supernus Merger
With Indivior shareholders set to control 56.5% of the entity post-merger, the New York-based law firm Monteverde & Associates PC has initiated an investigation into the proposed combination with Supernus Pharmaceuticals. The probe seeks to determine if the deal offers fair value to existing investors before the transaction closes.
Monteverde & Associates PC, recognized in the 2025 ISS Securities Class Action Services Report, has previously litigated cases reaching the U.S. Supreme Court. Shareholders seeking further details on the investigation or wishing to discuss potential legal implications may reach the firm at (212) 971-1341 or via email at jmonteverde@monteverdelaw.com.
Comments (0)
No comments yet. Be the first!